Tweets
How does @US_FDA see Tyk2 inh: part of or separate to JAKi class?
“I don’t think I’m in a position to make a call on this at this meeting, but certainly Tyk2 is a JAK”
Tantalising end to a great session at #ACR21. Feels like the audience could have questions for days. @RheumNow
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
#ACR21 plenary#1424. JUNIPERA study for Secukinumab for ERA, JPsA
⭐️Time to disease flare longer in SEC vs PBO
⭐️Sustained improvement up to wk 104
▶️Rapid decrease of JADAS-27 in initial open-label portion of study
https://t.co/m5bl9Ho163 @Rheumnow https://t.co/wnEdxeYfjh
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
Network meta-analysis assessed comparative risk of respiratory tract infection (RTI) with different b/ts DMARD in PsA
⭐️Abatacept 🔽likelihood RTIs compared ADM/ apremilast/ CTZ/ GOL/TOF
⭐️Apremilast 🔼likelihood RTIs compared INX /secukinumab
Abst # 1359 #ACR21 @RheumNow
swethaann23 @swethaann23 ( View Tweet )
4 years 8 months ago
Abst1305 #acr21 @RheumNow undiagnosed depression in AxSpA: 9.9% pts w/abnormal HADs-D scores,23.9% moderate to severe PHQ-9 scores. F had higher mean HADs-D scores than M, w/abnormal scores in 19% of F & 6% M. significantly worse BASDAI&AQoL scores in axSpA pts w/abnormal HADs-D https://t.co/sPkGPcITCs
Olga Petryna @DrPetryna ( View Tweet )
4 years 8 months ago
Knee OA novel measure of structure and function - Quantitative radiographic OA scores (QROS) software that measures medial minimum joint space width (mJSW) and other measures in the tibiofemoral compartment predicts time to TKA. Model well calibrated @rheumnow #ACR21 #abst1051 https://t.co/9LKlb7bZO0
Bella Mehta @bella_mehta ( View Tweet )
4 years 8 months ago
Characteristics of #uveitis w/axSpA seen in patients of this study:
👁🗨14.6%➡uveitis
👁🗨All acute, anterior & 93% unilateral
👁🗨Delay in dx & ⬆ HLAB27+
No diff. in TNFi use
Consistent fact: Uveitis is the ⬆ common extra-articular manifestation in axSPA
@RheumNow #ACR21 abs1324 https://t.co/6qC8RxxBrM
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
Study comparing TNFi vs SEC in PsA pts w/ active US confirmed enthesitis finds superiority of TNFi (ADA, CTZ, ETN) in regards to active entheseal disease. Abs 1356 #ACR21 #RheumNow @RheumNow https://t.co/BvZZsTP3Ta https://t.co/G5cWrQgqDC
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 8 months ago
#ACR21 Abs#1425. AURORA2 - voclosporin for LN extension
⭐️216/357 pts continued into 2-yr study
⭐️Mean UPCR at month 30: 0.58 in VOC vs 1.3 control. eGFR ⬇️ in VOC, remains stable
⭐️No new AEs
@Rheumnow https://t.co/m5bl9Ho163 https://t.co/VVGOCd9vmC
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
What better than a tweet on a #ACR21 study of tweets! 😂
Using Twitter Firehose data stream - yes we should do a study just during the ACR week...!
Fake tweets exists but low in the rheumatology community!
@rheumnow #abst1068
Paper - https://t.co/ekguL5qXen https://t.co/rfy7vZlXOn
Bella Mehta @bella_mehta ( View Tweet )
4 years 8 months ago
Abst1356 #acr21 @RheumNow TNFi vs SEC in active US confirmed enthesitis: mean ActiveMASEI score ⬇️ 4.37 w/TNFi vs 2.22 secukinumab (p = 0.030). Secucinumab leads in regards to the PASI & DLQI score with Sec vs TNFi ( 3.44 vs 1.03 p = 0.001 & 5.57 vs 1.35 p = 0.005 respectively https://t.co/fGTxzvGY99
Olga Petryna @DrPetryna ( View Tweet )
4 years 8 months ago
FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal
- Do we need post marketing RCTs BARI and UPA: one in prog for BARI, not for UPA
- 1133, why high CI of 1.8? Based on stricter margins based on prior studies with diabetes
- Are Tyk2 a worry? to early
-#ACR21
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal
- Bari OK in COVID but now CV risk: theres a limit (14d) for Bari in COVID
- CV Risk applied to all JAKi - largely because all have same indication, same populations at risk
#ACR21
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
